47. Buerger disease Clinical trials / Disease details
Clinical trials : 9 / Drugs : 14 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 16
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05698979 (ClinicalTrials.gov) | January 30, 2023 | 5/1/2023 | Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease | Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease | Buerger Disease;Raynaud Syndrome | Drug: BOTOX INJECTION | University Hospital, Toulouse | NULL | Not yet recruiting | 18 Years | N/A | All | 8 | Phase 3 | NULL |